Navigation Links
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Date:12/15/2008

tion endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the Company's ability to obtain sufficient financial resources to continue operations, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
4. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
7. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
8. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Tianyin Pharmaceutical Co., Inc. ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today updates the timeline for the ... The Company is scheduled to ... China Food & Drug Administration,s (CFDA) review in ...
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that the market ... $7.7 billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s ... out by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2
... BEIJING, March 1, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... or the "Company"), an emerging leader in the ... and homecare medical products in China, today announced ... community conferences in March: (Logo: ...
... Diagnostics, Inc. announced today that the WARFARIN Study ( W ... or A dults R eceiving Genetic Testing at ... nationwide to assess the utility of genetic testing to determine ... risk of serious bleeding or clotting events. Warfarin, the most ...
Cached Medicine Technology:Dehaier Medical Announces March Investor Presentations 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3
(Date:8/28/2014)... 28, 2014 Gurnick Academy of Medical ... program is re-accredited for the 5 years of the ... Technologists (ARMRIT). , “We are very proud to ... our program to make sure we provide the best ... interest in MRI field nowadays and I look forward ...
(Date:8/28/2014)... A chronic problem in winemaking is "stuck fermentation," when ... alcohol and carbon dioxide prematurely shuts down, leaving the ... can spoil the wine. , A team of researchers ... a biochemical communication system behind this problem. Working ... can reproduce itself -- the system enables bacteria in ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
(Date:8/28/2014)... smoking kills approximately 440,000 Americans each year, according ... It,s the leading cause of preventable death worldwide. ... resort to nicotine replacement therapies. , A ... University of Miami (UM) suggest that small dosages ... harmful to human musculoskeletal system, due to overuse. ...
(Date:8/28/2014)... Lifesmart (formerly Source Network Sales and ... saunas, spas and hot tubs, today unveiled its entry ... purifiers, and price point multi-function tower fans. , “These ... established product lines and they will help us even ... less dependent on fourth quarter weather trends. Additionally ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:DeVincenzo study breakthrough in RSV research 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3Health News:Lifesmart Unveils New Line of Air Conditioners, Dehumidifiers, Humidifiers, Air Purifiers and Price Point Multi-Function Tower Fans Expanding the lifesmart zone Brand 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, April ... take calcium supplements to prevent bone deterioration may, in fact, be ... previous studies with similar findings, the new conclusions don,t necessarily mark ... study released online April 19 in the BMJ . ...
... at the University of Pennsylvania School of Medicine are delving ... of chromosomes. Recent work, e-published in Nature Structural & ... telomeres, can be protected by caps made up of specialized ... Telomere caps are like a knot at the end of ...
... major discovery about an enzyme,s structure has opened a window ... have determined the structure of a nuclease that will help ... for cancer research. DNA repair pathways are very important ... tools the cell uses to do those repairs are not ...
... that will test whether heart disease drugs can be used ... class of drugs - known as statins - can prevent ... cent of pregnant women in the UK. The ... research showing that statins, which are prescribed to lower heart ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- ... to curb misuse of extended-release and long-acting opioid pain killers ... Risk Evaluation and Mitigation Strategy (REMS) is part of a ... reduce overall prescription drug abuse in the United States. ...
... The European College of Neuropsychopharmacology (ECNP) is pleased ... the 2011 ECNP Neuropsychopharmacology Award in Basic Science ... the brain adenosine system. The ECNP Neuropsychopharmacology Award ... neuropsychopharmacology and closely related disciplines. The award is ...
Cached Medicine News:Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 2Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 3Health News:Ends of chromosomes protected by stacked, coiled DNA caps 2Health News:Ends of chromosomes protected by stacked, coiled DNA caps 3Health News:Nature's elegant solution to repairing DNA in cancer, other conditions 2Health News:Heart drugs could cut blood pressure risks in pregnancy 2Health News:FDA Looks to Crack Down on Misuse of Opioid Painkillers 2Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2
Stainless steel. Lamp is in fiberoptic handle. Green color coding. The blade includes a port that permits delivery of oxygen or other gas mixtures during intubation....
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Stainless steel. Lamp supplied with ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
Medicine Products: